http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H04360899-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6831b19bfc354357342f7c7da79fc162 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 1991-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17d0470dd3791a4b29044da8eb9ca51a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7557744dedad6b22e2e3795a56b1a3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed79991ddb0b91c301200deda4b4f182 |
| publicationDate | 1992-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H04360899-A |
| titleOfInvention | Production of bioactive pentapeptide |
| abstract | PURPOSE: To obtain the subject peptides having an allergy blocking effect with industrial advantage by condensing L-aspartyl-L-prolyl-L-arginine in which the side chains are protected with an amino-protected L-aspartyl-L-serine and subsequently eliminating the protecting groups. n CONSTITUTION: A tripeptide (e.g. N-t-butoxycarbonyl-(β benzyl-L-aspartyl-L- prolyl-NG-nitro-L-arginine benzyl ester) represented by formula I (R 1 and R 3 are carboxylic group-protecting group; R 2 is guanidino group-protecting group; R 6 is amino-protecting group) is, after removal of the amino-protecting groups from the aspartic acid part thereof, subjected to fragment condensation with an amino-protected type dipeptide (e.g. N-t-butoxycarbonyl-β-benzyl-L-aspartyl-L- serine) of formula II (R 4 is amino-protecting group; R 5 is carboxyl-protecting group) to obtain a pentapeptide of formula III. The protecting groups are subsequently eliminated, thus obtaining the objective L-aspartyl-L-serin-L-aspartyl-L- prolyl-L-arginine) of formula IV. n COPYRIGHT: (C)1992,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022196797-A1 |
| priorityDate | 1991-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.